Final Agenda Now Available View Brochure

Registration Deadline Next Friday for The #1 Immunogenicity & Bioassay Event in the U.S.

Join leading FDA, industry, and academic experts at CHI’s 18th Annual Immunogenicity & Bioassay Summit, taking place October 19–22, 2026, in Alexandria, VA + virtually.

This premier summit will feature comprehensive coverage of immunogenicity risk assessment, bioassay development, clinical strategies, and regulatory expectations, including talks from 8 confirmed FDA speakers. The program also features interactive discussions, expert-led training seminars and short courses, a dynamic exhibit and poster hall, and much more.

The 2026 attendee list is now live. Explore who’s attending and join us this October for the insights and high-value networking opportunities you need to move your programs forward.

Programs Bringing Together Top Industry, Academia & Regulatory Authorities

STREAMS

OCTOBER 19

OCTOBER 20-21

OCTOBER 21-22

IMMUNOGENICITY

Symposium:
Immunology for Biotherapeutics

Immunogenicity Assessment & Clinical Relevance

Immunogenicity Prediction
& Control

BIOASSAYS

Training Seminar:
Biostatistics for Beginners

Training Seminar:
Statistical Methods for Bioassay Development

Optimizing Bioassays for Biologics

Confirmed FDA Speakers Include:

Yow-Ming Wang, PhD

Yow-Ming Wang, PhD
CDER, FDA

Wojciech Jankowski, PhD

Wojciech Jankowski, PhD
CBER, FDA

Daniel Lagassé, PhD

Daniel Lagassé, PhD
CBER, FDA

Zuben Sauna, PhD

Zuben Sauna, PhD
CBER, FDA

Leila Abdelhamid, PhD

Leila Abdelhamid, PhD
CBER, FDA

VIEW FDA SPEAKERS

Hear From Industry and Academic Experts

Amy Rosenberg, MD

Amy Rosenberg, MD
Senior Director, Bioanalytical Sciences, Regeneron Pharmaceuticals

Mohsen Rajabi Abhari, PhD

Mohsen Rajabi Abhari, PhD
Director, Scientific Governance PK Sciences Drug Disposition, Novartis

Michael Swanson, PhD

Michael Swanson, PhD
Director Immunogenicity Lead, GSK

Vibha Jawa, PhD

Vibha Jawa, PhD
CSO, Epivax Inc.

Weifeng Xu, PhD

Weifeng Xu, PhD
Director, Bioanalytical, Merck

Weiping Shao, PhD

Weiping Shao, PhD
Senior Director and Head of Regulatory Bioanalysis, AstraZeneca

Smanla Tundup, PhD

Smanla Tundup, PhD
Director, R&D, Eli Lilly and Company

VIEW ALL SPEAKERS

Network with Industry Titans from the FDA, Regeneron, AstraZeneca, Eli Lilly, Merck, Johnson & Johnson, Bristol Myers Squibb, Genentech, Moderna, Novo Nordisk, Bayer & More!

View Photos & Videos

Top Reasons to Attend

Engage directly with FDA and global regulatory leaders shaping expectations for immunogenicity risk assessment, ADA/NAb strategies, and bioanalytical validation, and gain clarity on evolving guidance impacting your development programs.
Gain practical insights from industry and academic experts advancing immunogenicity prediction, assay development, clinical immunogenicity assessment, and emerging therapeutic modalities, with real-world case studies and lessons learned.
Participate in interactive discussions and panels designed to address real-world scientific and regulatory challenges, allowing you to benchmark approaches, ask questions, and exchange perspectives with peers.

Explore a dynamic exhibit and poster hall featuring innovative technologies, solution providers, and cutting-edge research, and discover new tools and partners to support your work.
Expand your network with scientists and decision-makers working across biologics, cell and gene therapies, vaccines, and novel drug platforms, fostering meaningful connections that extend beyond the event.
Leave with actionable strategies and valuable connections — this premier meeting delivers the scientific depth, regulatory clarity, and peer network you need to confidently move your programs forward.

VIEW MORE TESTIMONIALS

Thank You to Our 2026 Corporate Sponsors